Biofrontera Q1 2026 revenue rises 17% to $10.1 million; net loss widens to $4.8 million
Biofrontera reported first quarter 2026 revenue of $10.1 million, up about 17% from a year earlier, with gross margin near 80% after a restructured earnout following its October 2025 strategic transaction with Biofrontera AG. The net loss widened to $4.8 million from $4.2 million, though the loss per share improved to $0.41 from $0.47 on a higher share count, so shareholders get mixed signals on profitability.
Key points
- Revenue was $10.1 million versus $8.6 million, driven by about 16% growth in Ameluz units sold and a price increase in Q4 2025.
- Gross margin was about 80% versus about 62%; SG&A rose to $11.0 million from $8.7 million.
- Net loss was $4.8 million, or $0.41 per share, versus $4.2 million, or $0.47 per share; Adjusted EBITDA improved to $(3.6) million from $(4.4) million.
- Cash and cash equivalents were $6.3 million at March 31, 2026, with $70 thousand used in operations in the quarter.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.